Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.17
A's Cash-to-Debt is ranked lower than
63% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. A: 1.17 )
Ranked among companies with meaningful Cash-to-Debt only.
A' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.63  Med: 1.3 Max: No Debt
Current: 1.17
Equity-to-Asset 0.55
A's Equity-to-Asset is ranked lower than
56% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. A: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
A' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.5 Max: 0.71
Current: 0.55
0.31
0.71
Interest Coverage 9.68
A's Interest Coverage is ranked lower than
69% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. A: 9.68 )
Ranked among companies with meaningful Interest Coverage only.
A' s Interest Coverage Range Over the Past 10 Years
Min: 0.53  Med: 6.44 Max: 12.45
Current: 9.68
0.53
12.45
Piotroski F-Score: 8
Altman Z-Score: 4.31
Beneish M-Score: -2.51
WACC vs ROIC
10.87%
16.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 17.02
A's Operating Margin % is ranked higher than
83% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. A: 17.02 )
Ranked among companies with meaningful Operating Margin % only.
A' s Operating Margin % Range Over the Past 10 Years
Min: 1.05  Med: 11.85 Max: 16.32
Current: 17.02
1.05
16.32
Net Margin % 13.46
A's Net Margin % is ranked higher than
86% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. A: 13.46 )
Ranked among companies with meaningful Net Margin % only.
A' s Net Margin % Range Over the Past 10 Years
Min: -0.69  Med: 12.28 Max: 18.85
Current: 13.46
-0.69
18.85
ROE % 13.59
A's ROE % is ranked higher than
73% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. A: 13.59 )
Ranked among companies with meaningful ROE % only.
A' s ROE % Range Over the Past 10 Years
Min: -1.22  Med: 16.28 Max: 26.86
Current: 13.59
-1.22
26.86
ROA % 7.45
A's ROA % is ranked higher than
75% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. A: 7.45 )
Ranked among companies with meaningful ROA % only.
A' s ROA % Range Over the Past 10 Years
Min: -0.42  Med: 7.41 Max: 11.77
Current: 7.45
-0.42
11.77
ROC (Joel Greenblatt) % 68.64
A's ROC (Joel Greenblatt) % is ranked higher than
85% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. A: 68.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
A' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.79  Med: 44.69 Max: 84.13
Current: 68.64
7.79
84.13
3-Year Revenue Growth Rate 4.20
A's 3-Year Revenue Growth Rate is ranked lower than
54% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. A: 4.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
A' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 3.05 Max: 18.4
Current: 4.2
-22.9
18.4
3-Year EBITDA Growth Rate 5.40
A's 3-Year EBITDA Growth Rate is ranked higher than
55% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. A: 5.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
A' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -27.7  Med: 5.8 Max: 76.6
Current: 5.4
-27.7
76.6
3-Year EPS without NRI Growth Rate 29.10
A's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. A: 29.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
A' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37.7  Med: 11.2 Max: 135.6
Current: 29.1
-37.7
135.6
GuruFocus has detected 7 Warning Signs with Agilent Technologies Inc $A.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» A's 30-Y Financials

Financials (Next Earnings Date: 2017-08-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

A Guru Trades in Q2 2016

Columbia Wanger 883,642 sh (New)
Stanley Druckenmiller 220,300 sh (New)
Joel Greenblatt 171,934 sh (+1385.65%)
Ron Baron 28,000 sh (+21.74%)
Steven Cohen 52,100 sh (+7.64%)
Pioneer Investments 107,767 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 125,000 sh (unchged)
Chris Davis Sold Out
George Soros Sold Out
PRIMECAP Management 5,018,630 sh (-2.98%)
Vanguard Health Care Fund 3,231,150 sh (-11.79%)
Mario Gabelli 172,400 sh (-14.78%)
RS Investment Management 2,149,542 sh (-19.20%)
Jim Simons 419,000 sh (-44.52%)
Paul Tudor Jones 9,330 sh (-76.25%)
Keeley Asset Management Corp 21,500 sh (-79.68%)
» More
Q3 2016

A Guru Trades in Q3 2016

Joel Greenblatt 470,942 sh (+173.91%)
Stanley Druckenmiller 220,300 sh (unchged)
Ron Baron 28,000 sh (unchged)
Pioneer Investments Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Mario Gabelli 171,800 sh (-0.35%)
Keeley Asset Management Corp 21,385 sh (-0.53%)
Paul Tudor Jones 8,991 sh (-3.63%)
PRIMECAP Management 4,681,530 sh (-6.72%)
Columbia Wanger 703,334 sh (-20.41%)
Vanguard Health Care Fund 2,540,550 sh (-21.37%)
Steven Cohen 33,600 sh (-35.51%)
Jim Simons 12,400 sh (-97.04%)
» More
Q4 2016

A Guru Trades in Q4 2016

Jim Simons 766,200 sh (+6079.03%)
Steven Cohen 370,300 sh (+1002.08%)
Paul Tudor Jones 13,571 sh (+50.94%)
Keeley Asset Management Corp 24,025 sh (+12.35%)
Ron Baron 28,000 sh (unchged)
Stanley Druckenmiller Sold Out
PRIMECAP Management 4,654,830 sh (-0.57%)
Mario Gabelli 170,400 sh (-0.81%)
Columbia Wanger 588,093 sh (-16.38%)
Vanguard Health Care Fund 1,889,350 sh (-25.63%)
Joel Greenblatt 324,174 sh (-31.16%)
» More
Q1 2017

A Guru Trades in Q1 2017

Pioneer Investments 50,326 sh (New)
Steven Cohen 996,237 sh (+169.04%)
Columbia Wanger 621,835 sh (+5.74%)
PRIMECAP Management 4,765,730 sh (+2.38%)
Ron Baron 28,000 sh (unchged)
Vanguard Health Care Fund 1,889,350 sh (unchged)
Mario Gabelli 165,000 sh (-3.17%)
Jim Simons 559,100 sh (-27.03%)
Paul Tudor Jones 9,073 sh (-33.14%)
Joel Greenblatt 67,191 sh (-79.27%)
» More
» Details

Insider Trades

Latest Guru Trades with A

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3825
Compare:NYSE:Q, NYSE:DGX, NAS:IDXX, NYSE:LH, OTCPK:SSMXY, OTCPK:ERFSF, OTCPK:BMXMF, NAS:QGEN, NYSE:PKI, OTCPK:SUVPF, NYSE:BIO.B, NAS:INCR, NAS:DXCM, NAS:ICLR, OTCPK:CZMWF, NAS:PRAH, NYSE:CRL, NAS:VWR, NAS:BRKR, NYSE:ALR » details
Traded in other countries:AG8.Germany,
Headquarter Location:USA
Agilent Technologies Inc provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets.

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading health-care firm. Today, Agilent's measurement technologies serve a broad base of customers within three operating segments: life science and applied equipment (50% of sales), cross lab (which includes consumables and services at 33%), and diagnostics and genomics (17%). The United States and Europe account for 36% and 30% of revenue, respectively, with China and Japan accounting for the majority of remaining sales. Agilent is headquartered in California.

Ratios

vs
industry
vs
history
PE Ratio 33.43
A's PE Ratio is ranked lower than
56% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. A: 33.43 )
Ranked among companies with meaningful PE Ratio only.
A' s PE Ratio Range Over the Past 10 Years
Min: 2.75  Med: 15.6 Max: 48.52
Current: 33.43
2.75
48.52
Forward PE Ratio 27.93
A's Forward PE Ratio is ranked lower than
64% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. A: 27.93 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 33.43
A's PE Ratio without NRI is ranked lower than
56% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. A: 33.43 )
Ranked among companies with meaningful PE Ratio without NRI only.
A' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.2  Med: 15.84 Max: 301.43
Current: 33.43
5.2
301.43
Price-to-Owner-Earnings 35.94
A's Price-to-Owner-Earnings is ranked lower than
63% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. A: 35.94 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
A' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.5  Med: 15.71 Max: 194.42
Current: 35.94
2.5
194.42
PB Ratio 4.37
A's PB Ratio is ranked lower than
54% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. A: 4.37 )
Ranked among companies with meaningful PB Ratio only.
A' s PB Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.64 Max: 4.35
Current: 4.37
1.22
4.35
PS Ratio 4.50
A's PS Ratio is ranked lower than
54% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. A: 4.50 )
Ranked among companies with meaningful PS Ratio only.
A' s PS Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.89 Max: 7.73
Current: 4.5
0.59
7.73
Price-to-Free-Cash-Flow 29.71
A's Price-to-Free-Cash-Flow is ranked lower than
56% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. A: 29.71 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
A' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.4  Med: 15.32 Max: 68.05
Current: 29.71
5.4
68.05
Price-to-Operating-Cash-Flow 24.14
A's Price-to-Operating-Cash-Flow is ranked lower than
58% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. A: 24.14 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
A' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.31  Med: 12.53 Max: 39.2
Current: 24.14
4.31
39.2
EV-to-EBIT 25.18
A's EV-to-EBIT is ranked lower than
58% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. A: 25.18 )
Ranked among companies with meaningful EV-to-EBIT only.
A' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 13.7 Max: 249.8
Current: 25.18
4.9
249.8
EV-to-EBITDA 19.34
A's EV-to-EBITDA is ranked lower than
58% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. A: 19.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
A' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 10.9 Max: 31.7
Current: 19.34
4
31.7
Shiller PE Ratio 30.66
A's Shiller PE Ratio is ranked higher than
73% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. A: 30.66 )
Ranked among companies with meaningful Shiller PE Ratio only.
A' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.95  Med: 20.2 Max: 46.42
Current: 30.66
9.95
46.42
Current Ratio 3.20
A's Current Ratio is ranked higher than
63% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. A: 3.20 )
Ranked among companies with meaningful Current Ratio only.
A' s Current Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.57 Max: 4.08
Current: 3.2
1.61
4.08
Quick Ratio 2.74
A's Quick Ratio is ranked higher than
62% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. A: 2.74 )
Ranked among companies with meaningful Quick Ratio only.
A' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 2.07 Max: 3.44
Current: 2.74
1.04
3.44
Days Inventory 98.27
A's Days Inventory is ranked lower than
59% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. A: 98.27 )
Ranked among companies with meaningful Days Inventory only.
A' s Days Inventory Range Over the Past 10 Years
Min: 91.25  Med: 98.82 Max: 191.04
Current: 98.27
91.25
191.04
Days Sales Outstanding 57.15
A's Days Sales Outstanding is ranked higher than
60% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. A: 57.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
A' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.45  Med: 52.14 Max: 84.27
Current: 57.15
47.45
84.27
Days Payable 47.69
A's Days Payable is ranked lower than
55% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. A: 47.69 )
Ranked among companies with meaningful Days Payable only.
A' s Days Payable Range Over the Past 10 Years
Min: 43.61  Med: 51.45 Max: 79.36
Current: 47.69
43.61
79.36

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.83
A's Dividend Yield % is ranked lower than
54% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. A: 0.83 )
Ranked among companies with meaningful Dividend Yield % only.
A' s Dividend Yield % Range Over the Past 10 Years
Min: 0.31  Med: 1.13 Max: 1.42
Current: 0.83
0.31
1.42
Dividend Payout Ratio 0.31
A's Dividend Payout Ratio is ranked higher than
78% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.24 vs. A: 0.31 )
Ranked among companies with meaningful Dividend Payout Ratio only.
A' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.09  Med: 0.33 Max: 0.77
Current: 0.31
0.09
0.77
Forward Dividend Yield % 0.89
A's Forward Dividend Yield % is ranked lower than
55% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. A: 0.89 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.83
A's 5-Year Yield-on-Cost % is ranked lower than
70% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. A: 0.83 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
A' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.31  Med: 1.13 Max: 1.42
Current: 0.83
0.31
1.42
3-Year Average Share Buyback Ratio 0.90
A's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. A: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
A' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.5  Med: 1.05 Max: 11.4
Current: 0.9
-2.5
11.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 121.45
A's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. A: 121.45 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
A' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.8  Med: 11.68 Max: 1364
Current: 121.45
2.8
1364
Price-to-Tangible-Book 13.35
A's Price-to-Tangible-Book is ranked lower than
77% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. A: 13.35 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
A' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.1  Med: 3.89 Max: 12.49
Current: 13.35
1.1
12.49
Price-to-Intrinsic-Value-Projected-FCF 1.81
A's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
60% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. A: 1.81 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
A' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.2 Max: 2.86
Current: 1.81
0.62
2.86
Price-to-Median-PS-Value 2.38
A's Price-to-Median-PS-Value is ranked lower than
90% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. A: 2.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
A' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 0.94 Max: 3.92
Current: 2.38
0.38
3.92
Price-to-Graham-Number 4.45
A's Price-to-Graham-Number is ranked lower than
67% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. A: 4.45 )
Ranked among companies with meaningful Price-to-Graham-Number only.
A' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.84  Med: 2 Max: 9.54
Current: 4.45
0.84
9.54
Earnings Yield (Greenblatt) % 3.97
A's Earnings Yield (Greenblatt) % is ranked higher than
65% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. A: 3.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
A' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 7.3 Max: 20.2
Current: 3.97
0.4
20.2
Forward Rate of Return (Yacktman) % -4.84
A's Forward Rate of Return (Yacktman) % is ranked lower than
81% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. A: -4.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
A' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -10.2  Med: 8.4 Max: 78.6
Current: -4.84
-10.2
78.6

More Statistics

Revenue (TTM) (Mil) $4,324
EPS (TTM) $ 1.78
Beta1.55
Short Percentage of Float1.66%
52-Week Range $41.98 - 59.98
Shares Outstanding (Mil)321.00

Analyst Estimate

Oct17 Oct18 Oct19
Revenue (Mil $) 4,355 4,561 4,779
EPS ($) 2.11 2.36 2.64
EPS without NRI ($) 2.11 2.36 2.64
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.42%
Dividends per Share ($) 0.52 0.58 0.60
» More Articles for A

Headlines

Articles On GuruFocus.com
Agilent Technologies Raises Dividend 15% Dec 06 2016 
A Growth Stock in the Land of Value Stocks? Nov 30 2016 
A High-Tech Manufacturer With Excellent Growth Prospects Nov 03 2016 
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
Agilent, Apple and Canadian Pacific Are Among Larry Robbins' New Buys Dec 22 2015 
Should You Wait to Bet on Agilent Technologies? Dec 20 2015 
Larry Robbins Buys Cigna, Monsanto and Sells Out McDonald's Dec 09 2015 
Agilent Technologies Drop Means Buy Now Aug 27 2015 
Why Agilent Technologies is a "Hold" Jun 17 2015 
Buy the Keysight Technologies Spinoff After the Dip Jun 17 2015 

More From Other Websites
Edited Transcript of A earnings conference call or presentation 22-May-17 8:30pm GMT May 26 2017
Itron Inks Deal to Lower Water Losses in Sao Paulo, Brazil May 25 2017
Agilent Technologies Was the S&P 500’s Top Gainer on May 23 May 24 2017
Nokia and Agilent rise; Alexion, Kirkland's fall May 23 2017
Stocks Rise In Back And Forth Session; Will Alphabet Spin Off Waymo? May 23 2017
Netflix Is No 'House of Cards'; Feast On Wingstop: Analysts May 23 2017
The Hot Stock: Agilent Jumps 4.6% May 23 2017
Apple and Nokia go from enemies to frenemies, AutoZone miss weighs on auto parts sector,Toll... May 23 2017
Stocks: Slim Gains Turn Mixed; Nokia Surges On Apple Deal May 23 2017
Stocks rise as investors look past deadly bombing in UK, focus on Trump budget, oil May 23 2017
U.S. stocks set for 4th straight day of gains ahead of Fed speakers, flash PMIs May 23 2017
Early movers: NOK, AZO, A, TTWO, TOL, CSX, AZN, H, MGI & more May 23 2017
Yahoo Finance Live: Market Movers - May 23rd, 2017 May 23 2017
Agilent Technologies (A) Beats on Q2 Earnings & Revenues May 23 2017
After-hours buzz: H, A, CWH & TTWO May 22 2017
Agilent tops Street 2Q forecasts May 22 2017
Agilent shares up 4% on company earnings beat May 22 2017
Agilent Technologies Reports Second-Quarter Fiscal Year 2017 Financial Results May 22 2017
Market Recon: U.S. Dollar and Treasury Yields Are Still the Biggest Sources of Risk May 22 2017
Bulls Won the Day: Cramer's 'Mad Money' Recap (Friday 5/19/17) May 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)